Ibrutinib, an oral inhibitor of Bruton tyrosine kinase (Btk) used in patients affected by Waldenstrom macroglobulinemia associated with mutation in MYD88 or CXCR4 genes, demonstrated early improvement in three patients with anti-MAG neuropathy in [67]. The gene discussed is MAG; the disease is Waldenstrom macroglobulinemia.